- Home
- YOUL vs CRDF Comparison
YOUL vs CRDF Comparison
Compare YOUL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YOUL | CRDF |
|---|---|---|
| Founded | N/A | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.2M | 114.5M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | YOUL | CRDF |
|---|---|---|
| Price | $1.13 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 60.6K | ★ 989.3K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $0.78 | $1.48 |
| 52 Week High | $4.40 | $4.56 |
Technical Indicators
Market Signals| Indicator | YOUL | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 51.82 |
| Support Level | $1.09 | $1.48 |
| Resistance Level | $1.95 | $2.41 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 23.08 | 78.64 |
Price Performance
Historical ComparisonAbout YOUL Youlife Group Inc. American Depositary Shares
Youlife Group Inc is a blue-collar lifetime service provider with a nationwide network of 25 vocational schools under school management model and 25 curriculum development projects, covering a total of 37 cities or counties under 16 provinces of China.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.